Navigation Links
Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
Date:5/29/2014

COLUMBUS, Ohio A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL).

The study was published in the New England Journal of Medicine and led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James). It identifies gene mutations that cause ibrutinib resistance in CLL patients.

"Knowledge of these mutations is the first step in the development of drugs or drug combinations that might prevent or treat ibrutinib-resistant CLL," says co-principal investigator John C. Byrd, MD, director, division of hematology, and professor of medicine, of medicinal chemistry and of veterinary biosciences at Ohio State.

"Importantly, we saw none of these mutations in patients before they used ibrutinib," says Amy Johnson, PhD, associate professor of medicine in the division of hematology, an OSUCCC James researcher and a co-principal investigator of the study.

Ibrutinib (Imbruvica) works by permanently binding with a protein called Bruton's tyrosine kinase (BTK), a molecule that CLL cells need to grow and proliferate. BTK is one in a chain of proteins that relays growth signals from the surface of CLL cells to genes in the cell nucleus. By blocking BTK, ibrutinib halts the flow of these growth signals, and the CLL cells die (see illustration below).

The researchers found, however, that CLL cells can develop a mutation in BTK itself that weakens the ability of ibrutinib to bind with the protein. This leaves the drug less able to block BTK's action. The researchers also found two mutations in a protein that comes after BTK in the signaling pathway. Those mutations allow growth signals to travel the pathway even when BTK is blocked, rendering ibrutinib ineffective.

An estimated 15,700 new cases of CLL are expected in the United States in 2014, along with 4,600 deaths from the disease, which still has no cure.

Clinical trials have shown that ibrutinib is a highly effective drug for CLL and that it causes few serious side effects. Patients with relapsed CLL have shown a 71-percent overall response rate, and another 15-20 percent achieved a partial response. The estimated progression-free survival is 75 percent at 26 months.

"At this point, few patients taking ibrutinib have relapsed," says first author Jennifer Woyach, MD, assistant professor in the division of hematology and an OSUCCC James researcher. "But as more patients use the drug, it becomes more important to learn how resistance occurs and to have effective alternative therapies for patients who need them. And as other irreversible kinase inhibitors are developed for key signaling pathways in cancer, it will important to learn if this is a general pattern of resistance," she says

For this study, Byrd, Woyach, Johnson and their colleagues examined samples from six CLL patients who had developed ibrutinib resistance. The samples were obtained before treatment started and after resistance developed. Key technical findings included:

  • Ibrutinib resistance is due at least in part to a cysteine-to-serine mutation in BTK at the ibrutinib binding site and to mutations in a protein called PLC gamma 2;
  • Patients with lymphocytosis, which is an increase in the number of lymphocytes in the blood, showed no evidence of the resistance mutations;

  • The risk of relapse may be greatest for cases of CLL that show greater genomic instability, such as those with deletions in chromosomes 17 and 11.

"Overall, our findings emphasize the importance of this pathway in ibrutinib's mechanism of action in CLL," says Byrd, who holds the D. Warren Brown Designated Chair in Leukemia Research, directs the OSUCCC James CLL Experimental Therapeutics Laboratory and co-leads the Leukemia Research Program.


'/>"/>
Contact: Amanda Harper
amanda.harper2@osumc.edu
614-685-5420
Ohio State University Wexner Medical Center
Source:Eurekalert

Related medicine news :

1. Supermodel mouse reveals mechanisms that regulate metabolism, researchers find
2. Scientists decode epigenetic mechanisms distinguishing stem cell function and blood cancer
3. GW researcher discovers the mechanisms that link brain alertness and increased heart rate
4. Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches
5. Study reveals mechanisms cancer cells use to establish metastatic brain tumors
6. Study questions anti-cancer mechanisms of drug tested in clinical trials
7. WesternU Team Advances Understanding of Mechanisms of Learning and Neural Degeneration
8. Studies pinpoint specific brain areas and mechanisms associated with depression and anxiety
9. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
10. Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
11. New knowledge on molecular mechanisms behind breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment ... Florida. The event will be held at 7:30 pm on May 10th at the ... Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical stage ... the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna ... advances towards regulatory and clinical phases. , "This is another important step for ...
(Date:4/23/2017)... York, New York (PRWEB) , ... April 23, 2017 , ... ... begin to change. So is the process rendered in my Art and Music. These ... materials, nature, light, and silence the boundary of mystery culminate to the ultimate singularity.", ...
(Date:4/22/2017)... ... , ... Ecommerce sales have grown every year since the 1990’s, with 2016 ... consequences of rapid innovation and growth are often neglected in the name of progress. ... and individual’s job to give something back to the planet that provides the resources ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com released ... save an average of 70% when buying medication online from Canadian pharmacies verified ... when purchasing from other countries. The report (chart below) compares U.S. and foreign ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology: